Miroslava Didiasova
Overview
Explore the profile of Miroslava Didiasova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Didiasova M, Cesaro S, Feldhoff S, Bettin I, Tiegel N, Fussgen V, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791277
Succinic semialdehyde dehydrogenase (SSADH) is a mitochondrial enzyme involved in the catabolism of the neurotransmitter γ-amino butyric acid. Pathogenic variants in the gene encoding this enzyme cause SSADH deficiency, a...
2.
Didiasova M, Banning A, Tikkanen R
J Inherit Metab Dis
. 2023 Aug;
47(3):509-516.
PMID: 37606592
Due to the low number of patients, rare genetic diseases are a special challenge for the development of therapies, especially for diseases that result from numerous, patient-specific pathogenic variants. Precision...
3.
Brennenstuhl H, Didiasova M, Assmann B, Bertoldi M, Molla G, Jung-Klawitter S, et al.
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33203024
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare, monogenic disorder affecting the degradation of the main inhibitory neurotransmitter γ-amino butyric acid (GABA). Pathogenic variants in the gene that cause an...
4.
Didiasova M, Banning A, Brennenstuhl H, Jung-Klawitter S, Cinquemani C, Opladen T, et al.
Cells
. 2020 Feb;
9(2).
PMID: 32093054
Succinic semialdehyde dehydrogenase deficiency (SSADH-D) is a genetic disorder that results from the aberrant metabolism of the neurotransmitter γ-amino butyric acid (GABA). The disease is caused by impaired activity of...
5.
Kramer M, Markart P, Drakopanagiotakis F, Mamazhakypov A, Schaefer L, Didiasova M, et al.
Cell Signal
. 2019 Nov;
65:109432.
PMID: 31693876
Pirfenidone (PFD) is an orally available synthetic drug which has been approved for the treatment of idiopathic pulmonary fibrosis. In addition to its anti-fibrotic properties, PFD also exerts anti-tumor effects...
6.
Didiasova M, Schaefer L, Wygrecka M
Front Cell Dev Biol
. 2019 May;
7:61.
PMID: 31106201
Enolase is a glycolytic enzyme, which catalyzes the inter-conversion of 2-phosphoglycerate to phosphoenolpyruvate. Altered expression of this enzyme is frequently observed in cancer and accounts for the Warburg effect, an...
7.
Papp R, Nagaraj C, Zabini D, Nagy B, Lengyel M, Skofic Maurer D, et al.
Eur Respir J
. 2019 Apr;
53(6).
PMID: 31023847
Our systematic analysis of anion channels and transporters in idiopathic pulmonary arterial hypertension (IPAH) showed marked upregulation of the Cl channel TMEM16A gene. We hypothesised that TMEM16A overexpression might represent...
8.
Zucker M, Wujak L, Gungl A, Didiasova M, Kosanovic D, Petrovic A, et al.
Biochim Biophys Acta Mol Basis Dis
. 2019 Mar;
1865(6):1604-1616.
PMID: 30910704
Pulmonary hypertension (PH) is characterized by a thickening of the distal pulmonary arteries caused by medial hypertrophy, intimal proliferation and vascular fibrosis. Low density lipoprotein receptor-related protein 1 (LRP1) maintains...
9.
Kwapiszewska G, Gungl A, Wilhelm J, Marsh L, Thekkekara Puthenparampil H, Sinn K, et al.
Eur Respir J
. 2018 Sep;
52(5).
PMID: 30166321
Despite the beneficial effects of pirfenidone in treating idiopathic pulmonary fibrosis (IPF), it remains unclear if lung fibroblasts (FB) are the main therapeutic target.To resolve this question, we employed a...
10.
Didiasova M, Wujak L, Schaefer L, Wygrecka M
Cell Signal
. 2018 Aug;
51:257-265.
PMID: 30118759
Factor XII (FXII) is a protease that is mainly produced in the liver and circulates in plasma as a single chain zymogen. Following contact with negatively charged surfaces, FXII is...